Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: Retrospective analysis of already archived samples
- Registration Number
- NCT00911196
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. This will be done retrospectively using archived hepatocellular carcinoma tissue samples.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- The patient has pathologically proven hepatocellular carcinoma (any stage)
- All the data required are available from patient's records
Exclusion Criteria
N/A
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group A Retrospective analysis of already archived samples -
- Primary Outcome Measures
Name Time Method The prognostic character of the expression of the tumor antigens At the time of analysis Expression of c-MET in the same hepatocellular carcinoma tumor samples At the time of analysis The proportion of hepatocellular carcinoma patients whose tumor tissue expresses specific tumor antigens. At the time of analysis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
GSK Investigational Site
🇹🇭Chiangmai, Thailand